

# JOHNSON & JOHNSON

Reported by  
**WENGEL KATHRYN E**

## FORM 3

(Initial Statement of Beneficial Ownership)

Filed 07/11/18 for the Period Ending 07/02/18

Address	ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ, 08933
Telephone	732-524-2455
CIK	0000200406
Symbol	JNJ
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	01/01

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
<b>Wengel Kathryn E</b>			<b>7/2/2018</b>		<b>JOHNSON &amp; JOHNSON [JNJ]</b>		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<b>ONE JOHNSON &amp; JOHNSON PLAZA</b>			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>EVP, Chief GSC Officer /</b>				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
<b>NEW BRUNSWICK, NJ 08933</b>					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<b>Common Stock</b>	<b>34290.0363</b>	<b>D</b>	
<b>Common Stock</b>	<b>17.0000</b> (1)	<b>I</b>	<b>By 401k</b>
<b>Common Stock</b>	<b>281.0000</b> (2)	<b>I</b>	<b>By ESOP</b>

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>1/11/2014</b>	<b>1/8/2021</b>	<b>Common Stock</b>	<b>8238.0000</b>	<b>\$62.2000</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>2/9/2013</b>	<b>2/7/2020</b>	<b>Common Stock</b>	<b>2017.0000</b>	<b>\$62.6200</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>1/18/2015</b>	<b>1/17/2022</b>	<b>Common Stock</b>	<b>7877.0000</b>	<b>\$65.3700</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>1/17/2016</b>	<b>1/13/2023</b>	<b>Common Stock</b>	<b>56410.0000</b>	<b>\$72.5400</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>2/11/2017</b>	<b>2/9/2024</b>	<b>Common Stock</b>	<b>35638.0000</b>	<b>\$90.4400</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>2/10/2018</b>	<b>2/9/2025</b>	<b>Common Stock</b>	<b>32762.0000</b>	<b>\$100.0600</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy)</b> (3)	<b>2/9/2019</b>	<b>2/8/2026</b>	<b>Common Stock</b>	<b>38945.0000</b>	<b>\$101.8700</b>	<b>D</b>	

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Employee Stock Options (Right to Buy) (3)</b>	<b>2/13/2020</b>	<b>2/13/2027</b>	<b>Common Stock</b>	<b>42965.0000</b>	<b>\$115.6700</b>	<b>D</b>	
<b>Employee Stock Options (Right to Buy) (3)</b>	<b>2/12/2021</b>	<b>2/11/2028</b>	<b>Common Stock</b>	<b>33044.0000</b>	<b>\$129.5100</b>	<b>D</b>	
<b>Restricted Share Units (4)</b>	<b>2/8/2019</b>	<b>(4)</b>	<b>Common Stock</b>	<b>5882.0000</b>	<b>(4)</b>	<b>D</b>	
<b>Restricted Share Units (4)</b>	<b>2/12/2021</b>	<b>(4)</b>	<b>Common Stock</b>	<b>1658.0000</b>	<b>(4)</b>	<b>D</b>	
<b>Restricted Share Units (4)</b>	<b>2/13/2020</b>	<b>(4)</b>	<b>Common Stock</b>	<b>7592.0000</b>	<b>(4)</b>	<b>D</b>	

**Explanation of Responses:**

- (1) Shares held in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (6/30/2018).
- (2) Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (6/30/2018).
- (3) Vested and exercisable one day after the third anniversary of the date of the grant.
- (4) Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.

**Remarks:**

wengelpoa.txt

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>Wengel Kathryn E ONE JOHNSON &amp; JOHNSON PLAZA NEW BRUNSWICK, NJ 08933</b>			<b>EVP, Chief GSC Officer</b>	

**Signatures**

**Linda E. King, as attorney-in-fact for Kathryn E. Wengel**

**7/11/2018**

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**POWER OF ATTORNEY**

**Executive Officers**

Know all persons by these presents, that the undersigned hereby constitutes and appoints each of Thomas J. Spellman III, Tina French, Linda E. King, Maria Frucci and Michelle Ryan, signing singly, as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer of Johnson & Johnson (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the "Exchange Act") and Form 144 in accordance with Rule 144 of the Securities Act of 1933, as amended (the "Securities Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, 5 and 144 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys -in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act or Rule 144 of the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports pursuant to Section 16 of the Exchange Act with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

*/s/ Kathryn E. Wengel*  
Name: *Kathryn E. Wengel*  
Date: *July 3, 2018*